Back to search results

Individualized Cancer Therapy for Aggressive Cancers

This study is looking at whether using information about your cancer's unique molecular profile can help doctors choose the best treatment for aggressive cancers. Researchers will compare a targeted agent, chosen by a Molecular Tumor Board based on your cancer's profile, with standard of care agent, which is your doctor's usual choice of treatment. You could be eligible if you are 18 or older and have an aggressive solid cancer with a high risk of death within two years. The main goal is to see if this personalized approach leads to more patients receiving a "matched" treatment after 8 months. The study is currently unclear on its recruitment status.

Study design
This is an open-label, non-randomized study aiming to enroll 400 participants. It is designed to evaluate a strategy of molecular matching across different cancers.
What's involved
If you join, your tumor tissues or blood will be molecularly profiled. You will then receive either a targeted therapy or your doctor's choice of standard therapy.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for measuring matched treatment is at 8 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05674825

Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses

Recruiting
PHASE1Ages 18+InterventionalTreatment
Medical College of Wisconsin
~400 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:Targeted agentStandard of care agent

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Matched treatment
Measured over 8 months

Conditions

Cancer

Explore related trials

Ampulla of Vater CarcinomaAppendix CarcinomaCholangiocarcinomaColorectal CarcinomaEsophageal AdenocarcinomaGallbladder CarcinomaGastric AdenocarcinomaGastrointestinal Stromal TumorHepatocellular CarcinomaLung Non-Small Cell CarcinomaMalignant Head and Neck NeoplasmMalignant Neoplasm of Unknown PrimaryMalignant Ovarian NeoplasmMelanomaPancreatic Ductal AdenocarcinomaSarcomaSmall Intestinal AdenocarcinomaSolid NeoplasmTriple-Negative Breast CarcinomaUrothelial Carcinoma

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Hui-Zi Chen, MD, PhD · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin
  • Razelle Kurzrock, MD · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin

Who to contact

Medical College of Wisconsin Cancer Center Clinical Trials Office
[email protected]
866-680-0505 · ext. 8900
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Not a female of childbearing potential (FCBP), defined as all female patients that were not in post-menopause for at least one year or are surgically sterile, OR
An FCBP must have a negative serum pregnancy test and agree to use at least one form of pregnancy prevention during the study for at least one month after treatment discontinuation unless otherwise noted by the agent(s) USPI or IB, which the FCBP must follow.

What this trial measures

  • Matched treatment8 months

    The number of subjects who receive matched treatment based on multiomic profiling analysis and MTB recommendations.